

Review Form 1.6

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	Ms_JAMPS_88173
Title of the Manuscript:	Use of Prazosin for PTSD in Adolescents is Associated with Longer Inpatient Psychiatric Hospitalization
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljamps.com/index.php/JAMPS/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	<p>There must be acknowledgement, as this is not a RDBCT, that the decision to initiate Prazosin could have been associated with more severe symptoms of PTSD than those that did not require Prazosin, and it is the increased severity of symptoms that is more closely related to length of stay. There was no objective measure of PTSD symptoms to determine clinical severity. All effort should be made to show that there is only an association and cannot determine causality; statements suggesting that Prazosin should be avoided to prevent lengthy of stay issues would be an overreach based on this data. Not just general prospective studies, but RCTs that control for PTSD symptom severity would be beneficial in the future. Would mention that.</p> <p>The suggestion at the end regarding weighing the costs and benefits must be weighed in that benefits were not measured in this study, as there was no systematic way to document/monitor improvement in PTSD symptoms in either the Prazosin group or the control group.</p> <p>Along those lines, last paragraph of Intro, would change the word "effect" in "determine the effect" to "association," as stated in abstract.</p> <p>Otherwise, there are very few studies regarding Prazosin use in adolescents, the data is still valuable and worth publishing, just need to be careful about interpretation of the data</p>	
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments	<p>Is there any similar data for Clonidine or Guanfacine in the same settings, and whether they are associated with increased lengths of stay? These medications would also be expected to have orthostatic vital sign changes</p>	

[Review Form 1.6](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Michael Shapiro
Department, University & Country	University of Florida, USA